Testing avapritinib for advanced GI stromal tumors
Part of Cancer, Digestive system clinical trials.
This study looks at how well avapritinib works and how safe it is for people with metastatic or unresectable gastrointestinal stromal tumors (GIST). It focuses on whether the tumor has certain marker and gene features and whether you can tolerate related medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older.
- Have confirmed GI stromal tumor (GIST) on tissue testing, with CD- and/or DOG-1 positive markers.
- Have at least one measurable tumor spot on scans (not just lymph nodes).
- Be starting or already treated with avapritinib as part of the study.
- Have good day-to-day functioning (ECOG performance status 0 to 2).
- The tumor should not be KIT or PDGFRA wild type.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies avapritinib, a targeted medicine, for people with advanced or returning gastrointestinal stromal tumors (GIST) whose tumor does not have PDGFRA exon 18 mutations. It aims to see how well the drug can shrink tumors or control the disease.
This trial studies whether apatinib works better than the usual second-line targeted tablet for advanced gastrointestinal stromal tumor (GIST) after imatinib (or avatinib) no longer works. It may help people whose cancer has grown despite treatment or who couldn’t tolerate it.
This Phase 2 trial tests whether combining rivoceranib with paclitaxel can shrink or control advanced metastatic gastrointestinal stromal tumor (GIST) after standard medicines have stopped working. It may help people whose GIST has progressed despite prior treatments like imatinib, sunitinib, and regorafenib.
This trial tests whether adding radiation therapy to the drug ripretinib can help people with advanced gastrointestinal stromal tumors (GIST) that can't be removed by surgery and have stopped responding to other treatments. It aims to see if this combination is safe and effective.
This trial tests whether combining two oral medications, imatinib and fampridine, before surgery can shrink GIST tumors that have a specific KIT gene mutation. The goal is to improve surgical outcomes and potentially reduce the risk of the tumor coming back.
This study tests a new drug called DCC-2618 for patients with GIST (a rare stomach/intestinal cancer) who have already tried at least three other treatments. The goal is to see if this drug can slow or shrink tumors in patients whose cancer has stopped responding to standard medications.
Hear when a new Gastrointestinal Stromal Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.